- Tilray’s (TLRY) subsidiary, Aphria, has launched a new medical cannabis product
- Aphria made oral strips available to patients for quick relief using THC and CBD-rich varieties
- Each Aphria medical strip contains micronized cannabinoids that absorb directly into the bloodstream, providing patients with fast-acting relief from a range of conditions
- Tilray shares (TSX:TLRY) are up by 0.25 per cent and are trading at $11.90 per share as of 1:29 PM EST
Tilray (TLRY) makes medical cannabis oral strips powered by QuickStrip™ technology available to patients.
Tilray is a cannabis research, production, and distribution organization, whose subsidiary, Aphria, launched a new oral strip with THC and CBD-rich varieties.
Using Aphria’s QuickStrip™ technology, the strips are thin, edible, and dissolve micronized cannabinoids that quickly absorb into the bloodstream for fast relief.
Tilray’s Chairman and CEO, Irwin D. Simon, said,
“[…] Aphria [is] relentlessly committed to investing in patient wellness through a portfolio of new innovative product offerings. […] We look forward to extending our leadership in medical cannabis and to delivering value for patients and shareholders alike.”
President at Tilray Canada, Blair MacNeil, added,
“At Aphria Medical, our goal is to be the trusted partner for patients by providing them with high-quality, precise, and efficacious medical cannabis treatment.”
